JP2022518060A5 - - Google Patents

Info

Publication number
JP2022518060A5
JP2022518060A5 JP2021543372A JP2021543372A JP2022518060A5 JP 2022518060 A5 JP2022518060 A5 JP 2022518060A5 JP 2021543372 A JP2021543372 A JP 2021543372A JP 2021543372 A JP2021543372 A JP 2021543372A JP 2022518060 A5 JP2022518060 A5 JP 2022518060A5
Authority
JP
Japan
Application number
JP2021543372A
Other languages
Japanese (ja)
Other versions
JP7712206B2 (ja
JP2022518060A (ja
JPWO2020160020A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015455 external-priority patent/WO2020160020A1/en
Publication of JP2022518060A publication Critical patent/JP2022518060A/ja
Publication of JP2022518060A5 publication Critical patent/JP2022518060A5/ja
Publication of JPWO2020160020A5 publication Critical patent/JPWO2020160020A5/ja
Priority to JP2025115594A priority Critical patent/JP2025148430A/ja
Application granted granted Critical
Publication of JP7712206B2 publication Critical patent/JP7712206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543372A 2019-01-28 2020-01-28 多発性骨髄腫の処置方法 Active JP7712206B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115594A JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962797876P 2019-01-28 2019-01-28
US62/797,876 2019-01-28
US201962847826P 2019-05-14 2019-05-14
US62/847,826 2019-05-14
US201962861954P 2019-06-14 2019-06-14
US62/861,954 2019-06-14
US201962899094P 2019-09-11 2019-09-11
US62/899,094 2019-09-11
US201962931014P 2019-11-05 2019-11-05
US62/931,014 2019-11-05
EP19306554.7 2019-12-03
EP19306554 2019-12-03
US201962943716P 2019-12-04 2019-12-04
US62/943,716 2019-12-04
PCT/US2020/015455 WO2020160020A1 (en) 2019-01-28 2020-01-28 Methods of treating multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115594A Division JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Publications (4)

Publication Number Publication Date
JP2022518060A JP2022518060A (ja) 2022-03-11
JP2022518060A5 true JP2022518060A5 (https=) 2023-02-22
JPWO2020160020A5 JPWO2020160020A5 (https=) 2023-02-22
JP7712206B2 JP7712206B2 (ja) 2025-07-23

Family

ID=69646031

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543372A Active JP7712206B2 (ja) 2019-01-28 2020-01-28 多発性骨髄腫の処置方法
JP2025115594A Pending JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115594A Pending JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Country Status (15)

Country Link
US (2) US11939390B2 (https=)
EP (2) EP4588484A3 (https=)
JP (2) JP7712206B2 (https=)
KR (1) KR20210120048A (https=)
CN (2) CN114026121A (https=)
AU (1) AU2020215692A1 (https=)
BR (1) BR112021014699A2 (https=)
CA (1) CA3127928A1 (https=)
CO (1) CO2021011034A2 (https=)
IL (2) IL321343A (https=)
MA (1) MA54860A (https=)
MX (1) MX2021009079A (https=)
SG (1) SG11202108029XA (https=)
TW (2) TWI904081B (https=)
WO (1) WO2020160020A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279065B2 (ja) 2013-03-13 2018-02-14 サノフイ 抗cd38抗体およびカーフィルゾミブを含む組成物
CN107135654B (zh) 2014-09-12 2021-10-29 加利福尼亚大学董事会 巨胞饮人类抗cd46抗体和靶向癌症疗法
US11939390B2 (en) 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma
US20210171650A1 (en) * 2019-05-14 2021-06-10 Sanofi Methods of administering anti-cd38 antibody
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
MX2022006882A (es) * 2019-12-05 2022-11-08 Sanofi Aventis Us Llc Formulaciones de anticuerpos anti-cd38 para administracion subcutanea.
EP4192511A1 (en) * 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugates targeting cd46 and methods of use thereof
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
US20240058464A1 (en) * 2021-01-07 2024-02-22 Fortis Therapeutics, Inc. Combination therapy with for46 for cancer
CN114219787B (zh) * 2021-12-17 2024-08-06 三峡大学 一种初诊多发性骨髓瘤预后分期系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
NZ727295A (en) * 2012-08-09 2018-06-29 Celgene Corp Treatment of immune-related and inflammatory diseases
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016282674B2 (en) * 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
KR20190091497A (ko) * 2016-12-02 2019-08-06 루비우스 테라퓨틱스, 아이엔씨. 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
US11939390B2 (en) 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2022518060A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)